Once Daily i.v. Busulfan and Fludarabine (i.v. Bu-Flu) Compares Favorably with i.v. Busulfan and Cyclophosphamide (i.v. BuCy2) as Pretransplant Conditioning Therapy in AML/MDS-Reference-Cited by-同舟云学术

Once Daily i.v. Busulfan and Fludarabine (i.v. Bu-Flu) Compares Favorably with i.v. Busulfan and Cyclophosphamide (i.v. BuCy2) as Pretransplant Conditioning Therapy in AML/MDS

Published:2008-06 Issue:6 Volume:14 Page:672-684
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Andersson Borje S.,de Lima Marcos,Thall Peter F.,Wang Xuemei,Couriel Daniel,Korbling Martin,Roberson Soonja,Giralt Sergio,Pierre Betty,Russell James A.,Shpall Elizabeth J.,Jones Roy B.,Champlin Richard E.

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference52 articles.

1. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy;Bhagwatwar;Cancer Chemother Pharmacol,1996

2. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects

3. Non-ablative versus reduced intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome. Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation;de Lima;Blood,2004

4. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity;Shimoni;Leukemia,2006

5. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan

Cited by 152 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT);Bone Marrow Transplantation;2024-09-13

2. Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial;Blood Cancer Journal;2024-08-21

3. Evaluating clinically translatable conditioning for platelet gene therapy in murine hemophilia A with inhibitors;Journal of Thrombosis and Haemostasis;2024-08

4. Busulfan-Fludarabine Versus Busulfan-Cyclophosphamide for Allogeneic Transplant in Acute Myeloid Leukemia: Long Term Analysis of GITMO AML-R2 Trial;2024-07-18

5. A network meta-analysis of the effectiveness of different basic preconditioning regiments in allogeneic hematopoietic stem cell transplantation;Hematology;2024-07-15